VRNA

Verona Pharma PLC

Add to Watchlist

Advanced Chart

0.000

-106.91(-100.000%)1D

High

Open

VWAP

Vol

Mkt Cap

1.25B

Low

Amount

EV/EBITDA(TTM)

Total Shares

81.08M

9.02B

EV/OCF(TTM)

P/S(TTM)

Verona Pharma plc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The Company has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. It has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The Company's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

126.38M

+245.07%

0.542

-439.06%

115.84M

+1959.08%

0.155

-138.75%

0.170

-130.36%

Estimates Revision

The market is revising Downward the revenue expectations for Verona Pharma plc (VRNA) for FY2025, with the revenue forecasts being adjusted by -4.24% over the past three months. During the same period, the stock price has changed by 1.37%.

Revenue Estimates for FY2025

Revise Downward

-4.24%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-77.29%

In Past 3 Month

Stock Price

Go Up

+1.37%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast VRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRNA is 107.00 USD with a low forecast of 107.00 USD and a high forecast of 107.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

10 Hold

0 Sell

Hold

Current: 0.000

Low

107.00

Averages

107.00

High

107.00

Current: 0.000

Low

107.00

Averages

107.00

High

107.00

H.C. Wainwright

Raghuram Selvaraju

Buy

Neutral

downgrade

$90 -> $107

2025-07-14

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$90 -> $107

2025-07-14

downgrade

Buy

Neutral

Reason

H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma to Neutral from Buy with a price target of $107, up from $90, after Merck said it will acquire Verona for $107 per American depository share. The firm does not expect any competitors to attempt to outbid Merck.

Roth Capital

Boobalan Pachaiyappan

Buy -> Neutral

downgrade

$116 -> $107

2025-07-10

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$116 -> $107

2025-07-10

downgrade

Buy -> Neutral

Reason

Roth Capital analyst Boobalan Pachaiyappan downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of $107, down from $116, following Merck's (MRK) $10B proposal to acquire all Verona for $107 per share or $10B.

Wolfe Research

Outperform -> Peer Perform

downgrade

2025-07-10

Reason

Wolfe Research

Price Target

2025-07-10

downgrade

Outperform -> Peer Perform

Reason

Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.

Truist

Buy

Hold

downgrade

$100 -> $107

2025-07-10

Reason

Truist

Price Target

$100 -> $107

2025-07-10

downgrade

Buy

Hold

Reason

Truist downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100, following Merck's (MRK) $10B proposal to acquire all Verona for $107 per share or $10B. Verona's Ohtu makes sense as the "anchor" drug to help grow Merck's existing footprint in respiratory franchise and be competitive against dupi, IL33s and more, the analyst tells investors in a research note.

Piper Sandler

Overweight -> Neutral

downgrade

$160 -> $107

2025-07-10

Reason

Piper Sandler

Price Target

$160 -> $107

2025-07-10

downgrade

Overweight -> Neutral

Reason

Piper Sandler downgraded Verona Pharma (VRNA) to Neutral from Overweight with a price target of $107, down from $160, after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.

Jefferies

Buy

Hold

downgrade

$140 -> $107

2025-07-09

Reason

Jefferies

Price Target

$140 -> $107

2025-07-09

downgrade

Buy

Hold

Reason

Jefferies downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, down from $140, after the company entered into an agreement under which Merck (MRK) will acquire it for $107 per American depository share, or $10B. Jefferies sees no regulatory risks for the deal.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Verona Pharma PLC (VRNA.O) is 66.51, compared to its 5-year average forward P/E of -66.34. For a more detailed relative valuation and DCF analysis to assess Verona Pharma PLC 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-66.34

Current PE

66.51

Overvalued PE

248.54

Undervalued PE

-381.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.12

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

23.86

Undervalued EV/EBITDA

-46.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

78.81

Current PS

0.00

Overvalued PS

221.04

Undervalued PS

-63.42